Sanofi's Tolebrutinib Under FDA Priority Review For Treating NrSPMS & Slowing Disability Progression
(RTTNews) - Sanofi (SNY), a French pharmaceutical and healthcare company, announced Tuesday that the US Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSP
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
- Who's exposed
- SNYSanofi Down
Companies named in the story.
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the briefHow this story developed
2 reports over 23h 56m-
NASDAQ Markets You're reading this Sanofi's Tolebrutinib Under FDA Priority Review For Treating NrSPMS & Slowing Disability Progression Bearish −31

